



Comparing the Efficacy of Inhaled Corticosteroid (ICS) Treatment in COPD Patients Based on Blood Eosinophilia: A Clinical Trial Study

Mohammad Kazem Momeni ¹, Omolbanin Afroshte ^{2,*}, Mohammad Ali Mashhadi ², Abolfazl Payandeh ³, Mahmoud Amirian ⁴, Mohadeseh Chahkandi ^{5,**}

¹ Infectious Disease and Tropical Medicine Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran

² Department of Internal Medicine, Ali Ebn Abtaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran

³ Community Nursing Research Center, School of Health, Zahedan University of Medical Sciences, Zahedan, Iran

⁴ School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

⁵ Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran

* Corresponding Author: Department of Internal Medicine, Ali Ebn Abtaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran. Email: o.afroshte@gmail.com

** Corresponding Author: Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran. Email: m.chahkandi365@gmail.com

Received 2023 July 3; Revised 2024 April 3; Accepted 2024 April 7.

Abstract

Background: Inhaled corticosteroids (ICSs) have been widely used in the maintenance therapy of chronic obstructive pulmonary disease (COPD). Eosinophilic airway inflammation is a recognized inflammatory endotype in COPD. Nevertheless, the benefits and risks of ICS treatment remain controversial.

Objectives: Therefore, in this study, we determine the frequency of eosinophilia in COPD patients and compare the effects of ICSs in patients with and without eosinophilia referring to the lung clinics of Zahedan University of Medical Sciences.

Methods: In this study, 58 COPD patients were examined. Peripheral blood smears (PBS) were collected from all patients, and they were randomly divided into 2 groups. First, a 6-minute walking test (6MWT) was performed on all patients. Thereafter, two groups of patients received standard treatment with the Symbicort spray for 3 months. They were followed for this period, and the 6MWT was performed again at the end of the 3 months.

Results: The mean results of the 6MWT test before and after intervention in the eosinophilia-positive group were 164.02 meters and 192.11 meters, respectively. Therefore, there was a significant difference in patient activity levels before and after ICSs ($P = 0.017$). In the eosinophilia-negative group, there was a significant difference in patient activity levels based on the 6MWT test before and after taking ICSs ($P < 0.001$). However, there was no difference in activity levels between the two groups before and after the intervention ($P = 0.68$ and $P = 0.36$).

Conclusions: Our finding showed that treatment with inhaled β_2 -agonists plus corticosteroids did not affect the response to this treatment in subjects' groups with and without eosinophilia compared to the pre-treatment conditions.

Keywords: Chronic Obstructive Pulmonary Disease, Inhaled Corticosteroid, Eosinophilia

1. Background

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, characterized by an abnormal inflammatory response and chronic, irreversible, and persistent airway restriction symptoms (such as shortness of breath, coughing, and sputum production) (1, 2). Chronic obstructive pulmonary disease affects more than 329

million individuals globally, and it is estimated that by 2060, more than 5.4 million patients will die from COPD exacerbations and related diseases each year (3, 4).

Initial management of COPD patients includes lifestyle modifications, especially smoking cessation, vaccination, and regular exercise programs. However, due to excessive mucus secretion, tissue destruction, and disruption of normal repair and defense mechanisms, inhaled preparations with different

pharmacologic effects, including inhaled corticosteroids (ICSs), Long-acting β_2 -agonists (LABAs), and long-acting muscarinic receptor antagonists (LAMAs) are indicated for maintenance therapy (5-7). Additionally, treatment for patients with stage 3 and 4 COPD (severe and very-severe stages) includes long-term oxygen therapy and lung transplantation (8).

The clinical manifestations of COPD are associated with the three arms known as chronic bronchitis, emphysema, and asthma, which ultimately lead to airflow obstruction (9). Eosinophilic airway inflammation, a key feature of asthma, is a recognized inflammatory endotype in COPD (10-12). Chronic obstructive pulmonary disease with eosinophilic inflammation [also known as Asthma-COPD overlap (ASO)] is defined as sputum eosinophils $\geq 3\%$ (13, 14). Assessment of eosinophilic airway inflammation using induced sputum samples is technically challenging and not always successful, decreasing the usefulness of the test in routine clinical practice. There is a reasonable correlation between blood eosinophil count and sputum count in COPD patients, so blood eosinophil count may be a more reasonable alternative (a differential count of 2% or higher in blood has a positive predictive value of 90% for a raised eosinophil count in induced sputum) (15, 16).

Inhaled corticosteroids are one of the main treatment options for reducing the risk of moderate to severe COPD exacerbations (17). Chronic obstructive pulmonary disease patients with predominantly eosinophilic airway inflammation (ACO) may benefit most from ICS administration. Nevertheless, the benefits and risks of ICS treatment remain controversial, especially given the increased risk of pneumonia (18, 19).

2. Objectives

Therefore, in this study, we determine the frequency of eosinophilia in COPD patients and compare the effects of ICSs in patients with and without eosinophilia referring to the lung clinics of Zahedan University of Medical Sciences.

3. Methods

This study was a prospective, longitudinal, single-blind clinical trial. The participants were COPD patients referred to the lung clinics at Ali Ebn Abitaleb Hospital, Zahedan, Iran. The diagnosis of COPD in these participants relied on patient history, physical

examination, chest X-ray findings, and spirometry data. Inclusion criteria for COPD were as follows: (1) Airway signs and symptoms (such as productive cough, dyspnea, and wheezing); (2) confirmed chronic airway obstruction (defined as forced expiratory volume in 1 second (FEV₁)/forced vital capacity (FVC) < 70% and FEV₁ < 80% of the predicted values by spirometry data, and FEV₁ reversibility after inhalation of 200 μ g salbutamol of < 12% of prebronchodilator FEV₁); (3) over 40 years of age; (4) patients who had been stable for 4 weeks prior to the initial visit and received optimal medical therapy. Exclusion criteria for participants included the coincidence of cardiovascular disease, eosinophilia-related disease (e.g., parasites, collagen-vascular disease, hematologic, and oncological disease), and COPD exacerbation within 4 weeks prior to the first visit.

To determine the sample size, we utilized the formula for assessing the superiority of the mean 6-minute walking test (6MWT) after the study compared to the baseline.

$$n = \frac{(z_{\alpha} + z_{\beta})^2 \sigma^2}{(\epsilon - \delta)^2} \quad (1)$$

Using the results of a pilot study containing four eligible patients ($\alpha = 0.05$, $\beta = 0.25$, $\sigma = 14.5$, $\epsilon = 9.5$, $\delta = 5$) where σ , ϵ , and δ are the standard deviation (SD) of the differences, mean differences, and the superiority margin for 6MWT, respectively, 58 patients were computed and selected to compare the effectiveness of ICSs. Eligible patients were selected after ethical approval of the plan by the Research Ethics Committees of Zahedan University of Medical Sciences (IR.ZAUMS.REC.1397.224) and the Iranian Registry of Clinical Trials (IRCT20181126041758N1). First, peripheral blood smears (PBS) were obtained from all patients, and based on the percentage of blood eosinophils, they were divided into 2 groups (the threshold was 2% eosinophils). A 6MWT was then performed on all patients, wherein the patient walked a distance of 30 meters in 6 minutes. During this test, the person was allowed to stop if they felt tired or experienced symptoms (like dyspnea, chest pain, etc.) until they were able to resume walking. Thereafter, two groups of patients received standard treatment with the Symbicort spray for 3 months (manufactured by AstraZeneca, France and distributed by Cobel Darou, Iran). They were followed for the period, and the 6MWT was performed again at the end of the 3-month period. After data collection, the information was entered into

SPSS software version 26. Comparisons of treatment effects for parametric data were performed by independent *t*-tests; otherwise, non-parametric equivalence tests such as Mann-Whitney were used.

4. Results

Among 58 COPD patients, 49 patients (84.5%) had negative eosinophilia, and the rest (9 patients, 15.5%) had positive eosinophilia. The mean age of the patients was 58.81 ± 14.4 years. Out of 58 patients, 34 (58.6%) were male, and 24 (41.4%) were female. There were no significant differences in the mean age ($P = 0.66$) and gender ($P = 0.72$) between patients with and without eosinophilia (Table 1). The average FEV1 and FEV1/FVC of COPD patients with positive eosinophilia were $52.78 \pm 20.66\%$ and 62.14 ± 20.9 , respectively. In addition, the FEV1 and FEV1/FVC of COPD patients with negative eosinophilia were 62.06 ± 18.58 and 74.89 ± 19.43 , respectively (Table 2). The mean 6MWT test before and after intervention in the eosinophilia-positive group was 164.02 ± 108.97 meters and 192.11 ± 101.02 meters, respectively. Therefore, there was a significant difference in patients' activity levels before and after taking ICSs ($P = 0.017$, Table 3). Furthermore, in the eosinophilia-negative group, there was a significant difference in patient activity levels based on the 6MWT test before and after taking ICSs (147.9 ± 54.62 meters and 169.22 ± 60.47 meters, respectively, $P < 0.001$). However, there was no significant difference in activity levels between the two groups at baseline and also after the intervention ($P = 0.68$ and $P = 0.36$, respectively).

Table 1. Chronic Obstructive Pulmonary Disease Patient's Demographic Characteristics Based on Positive or Negative Eosinophilia^a

Variables	Negative Eosinophilia	Positive Eosinophilia	P-Value
Age	58.4 ± 14.9	60.7 ± 11.8	0.66
Sex			0.72
Male	28 (57.1)	6 (66.7)	
Female	21 (42.9)	3 (33.3)	

^a Values are expressed as mean \pm SD or No. (%).

5. Discussion

Chronic obstructive pulmonary disease is a progressive disease often associated with irreversible respiratory complications. It is one of the most prevalent diseases globally, imposing significant morbidity on societies, economics, and health systems

worldwide. Currently, the primary focus in COPD management is to identify markers that aid in developing the best treatment plan for each patient, determining the response to the chosen plan, and predicting the prognosis of the disease (1). Although several studies have explored the relationship between eosinophilia and clinical outcomes in COPD patients, the benefits and risks of ICS treatment remain controversial. This study aims to investigate the efficacy of ICS treatment in COPD patients based on blood eosinophilia. The main findings of this study are as follows: (1) Treatment with ICS resulted in a significant difference in the 6MWT test between the eosinophilia-positive and eosinophilia-negative groups; (2) treatment with inhaled β_2 -agonists plus corticosteroids did not affect the response to this treatment in subjects' groups with and without eosinophilia compared to the pre-treatment conditions.

Our results indicate that there are no significant differences in patient activity levels based on the 6MWT test before and after taking ICSs between the two groups (the eosinophilia-positive and the eosinophilia-negative group). These findings align with those of Yousuf et al., who showed that there is no significant relationship between eosinophilia, health, and COPD complications in patients (20). However, a cohort study by Jabarkhil et al. (21) demonstrated that patients with eosinophilic COPD had no increased risk of disease progression compared to COPD patients without eosinophilia. In contrast to these results, Kitaguchi et al. found in a study that patients with COPD and asthmatic components, who had higher eosinophilia and sputum eosinophilic count than non-asthmatic COPD patients, showed a better response to ICSs treatment. It was concluded that initiating treatment earlier in these patients could be associated with a better response and greater reversibility (22). Another study demonstrated that in COPD patients with eosinophilia, treatment with inhaled β_2 -agonists plus corticosteroids is associated with a decrease in the frequency of acute attacks of the disease (23). Siddiqui et al. showed that peripheral blood eosinophilia in COPD patients is a predictor of the desired response to long-acting inhaled β_2 -agonists plus corticosteroids, which may be attributed to its inflammatory profile and better response to corticosteroid therapy (24).

These differences may arise because COPD and asthma can overlap, a situation known as Overlap Syndrome. Patients with this syndrome are presumed to

Table 2. The Average Forced Expiratory Volume in 1 (FEV1) and FEV1/FVC (Forced Vital Capacity) of Chronic Obstructive Pulmonary Disease Patients Based on Positive or Negative Eosinophilia

Characteristics	Eosinophilia Positive; Mean \pm SD	Eosinophilia Negative; Mean \pm SD	P-Value
Forced expiratory volume in 1	52.78 \pm 20.66	62.06 \pm 18.58	0.38
Forced expiratory volume in 1/ forced vital capacity	62.14 \pm 20.9	74.89 \pm 19.43	0.33

Table 3. Comparison of the Average Level of Activity in Patients with or Without Eosinophilia (Pre and Post-intervention)^a

Characteristics	Eosinophilia Positive	Eosinophilia Negative	P-Value
Pre-intervention 6-minute walking test (m)	164.02 \pm 108.97 (80.2 - 247.7)	147.9 \pm 54.62 (132.2 - 163.59)	0.68
Post-intervention 6-minute walking test (m)	192.11 \pm 101.02 (114.4 - 269.7)	169.22 \pm 60.47 (151.85 - 186.59)	0.36
Difference (m)	28.08 \pm 27.91 (6.63 - 49.5)	21.32 \pm 19.95 (15.58 - 27.25)	-
P-value	0.017	< 0.001	-

^a Values are expressed as mean \pm SD (95% CI).

exhibit different clinical characteristics and better responses to ICS treatments. The chronic airway inflammation in COPD differs significantly from asthma, which is typically characterized by inflammation and hyperresponsiveness throughout the airway without involvement of the lung parenchyma (25). Asthma patients who smoke may develop pathological features similar to COPD. Similarly, some COPD patients may manifest asthma-like symptoms, including a complex inflammatory pattern and increased eosinophilia. It has been reported that in COPD, an elevated eosinophil count in sputum is associated with an improvement in FEV1 following treatment with ICSs (26, 27).

While eosinophil count may serve as a suitable and accessible biomarker for COPD treatment and predicting response to ICSs (28), potential barriers such as comorbidities, the patient's current dosing regimen, and the lack of proven correlations between peripheral blood eosinophils and tissue eosinophils limit their use in routine medical therapy.

5.1. Conclusions

In this study, it was observed that despite significant differences in the activity levels of patients in the 6MW test after treatment with inhaled β 2-agonists plus corticosteroids in both patient groups with and without eosinophilia compared to pre-treatment conditions, the response to this treatment in subjects with peripheral blood eosinophilia showed no significant difference

compared to patients without eosinophilia. Additionally, there were no significant differences in age and gender in this study.

5.2. Recommendations

Considering the smaller sample size of patients in the eosinophil-positive group compared to the eosinophil-negative group, we recommend prospective multicenter randomized clinical trials with both smaller and larger sample sizes. Additionally, due to the limited feasibility of patient follow-up, we suggest conducting a similar study with full-time access to the patients to evaluate their response to treatment.

Acknowledgements

We are grateful to Ali Ebn Abitaleb and the center and ZAUMS colleagues for their support.

Footnotes

Authors' Contribution: Study concept and design: Dr Mohammad Kazem Momeni; acquisition of data: Omolbanin Afrosht; analysis and interpretation of data: Mohammad Kazem Momeni and Mohammad Ali Mashhadi; drafting of the manuscript: Mohadeseh Chahkandi; critical revision of the manuscript for important intellectual content: Mohadeseh Chahkandi and Abolfazl Payandeh; statistical analysis: Mahmoud Amirian.

Clinical Trial Registration Code: Code: IRCT20181126041758N1.

Conflict of Interests Statement: The authors have no conflict of interest.

Data Availability: The data presented in this study are uploaded during submission as a supplementary file and are openly available for readers upon request.

Ethical Approval: This current study was approved by the Research Ethics Committees of Zahedan University of Medical Sciences (IR.ZAUMS.REC.1397.224).

Funding/Support: The current research was funded by an internal medicine specialty thesis from Zahedan University of Medical Sciences (ZAUMS) (Thesis number: 8915).

References

- Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med.* 2017;**195**(5):557-82. [PubMed ID: 28128970]. <https://doi.org/10.1164/rccm.201701-0218PP>.
- Ullah R, Ashraf S. Chronic obstructive lung disease: A rising problem for the world. *Pakistan J Chest Med.* 2017;**23**(4):130-3.
- Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. *Respirol.* 2016;**21**(1):14-23. [PubMed ID: 26494423]. <https://doi.org/10.1111/resp.12660>.
- Chen H, Deng ZX, Sun J, Huang Q, Huang L, He YH, et al. Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD: A Meta-analysis of 60 Randomized Controlled Trials. *Chest.* 2023;**163**(1):100-14. [PubMed ID: 35921883]. <https://doi.org/10.1016/j.chest.2022.07.015>.
- Ambrosino N, Bertella E. Lifestyle interventions in prevention and comprehensive management of COPD. *Breathe (Sheff).* 2018;**14**(3):186-94. [PubMed ID: 30186516]. [PubMed Central ID: PMC6118879]. <https://doi.org/10.1183/20734735.018618>.
- G. B. D. Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med.* 2020;**8**(6):585-96. [PubMed ID: 32526187]. [PubMed Central ID: PMC7284317]. [https://doi.org/10.1016/S2213-2600\(20\)30105-3](https://doi.org/10.1016/S2213-2600(20)30105-3).
- Global Initiative for Chronic Obstructive Lung Disease. *Global strategy for the diagnosis, management and prevention of COPD-2021.* Philadelphia, Pennsylvania: Global Initiative for Chronic Obstructive Lung Disease; 2021, [cited 2023]. Available from: <http://www.goldcopd.org>.
- Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. *Eur Respir J.* 2019;**53**(5). [PubMed ID: 30846476]. <https://doi.org/10.1183/13993003.00164-2019>.
- Nakawah MO, Hawkins C, Barbandi F. Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome. *J Am Board Fam Med.* 2013;**26**(4):470-7. [PubMed ID: 23833163]. <https://doi.org/10.3122/jabfm.2013.04.120256>.
- Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2018;**13**:335-49. [PubMed ID: 29403271]. [PubMed Central ID: PMC5777380]. <https://doi.org/10.2147/COPD.S152291>.
- Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. *Eur Respir J.* 2014;**44**(6):1697-700. [PubMed ID: 25323230]. <https://doi.org/10.1183/09031936.00162414>.
- Cheng SL, Lin CH. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. *Int J Chron Obstruct Pulmon Dis.* 2016;**11**:2341-8. [PubMed ID: 27703344]. [PubMed Central ID: PMC5036601]. <https://doi.org/10.2147/COPD.S115132>.
- Barrecheuren M, Esquinas C, Miravittles M. The asthma-COPD overlap syndrome: a new entity? *COPD Res Practice.* 2015;**1**(1). <https://doi.org/10.1186/s40749-015-0012-z>.
- Hiles SA, Gibson PG, McDonald VM. Disease burden of eosinophilic airway disease: Comparing severe asthma, COPD and asthma-COPD overlap. *Respirol.* 2021;**26**(1):52-61. [PubMed ID: 32428971]. <https://doi.org/10.1111/resp.13841>.
- Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. *Int J Chron Obstruct Pulmon Dis.* 2016;**11**:1495-504. [PubMed ID: 27445469]. [PubMed Central ID: PMC4936821]. <https://doi.org/10.2147/COPD.S100338>.
- Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. *Lancet Respir Med.* 2017;**5**(12):956-67. [PubMed ID: 29146301]. [PubMed Central ID: PMC5849066]. [https://doi.org/10.1016/S2213-2600\(17\)30432-0](https://doi.org/10.1016/S2213-2600(17)30432-0).
- Dransfield MT, Bourbeau J, Jones PW, Hanaia NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. *Lancet Respir Med.* 2013;**1**(3):210-23. [PubMed ID: 24429127]. [https://doi.org/10.1016/S2213-2600\(13\)70040-7](https://doi.org/10.1016/S2213-2600(13)70040-7).
- Cheng SL. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis. *Int J Chron Obstruct Pulmon Dis.* 2018;**13**:2775-84. [PubMed ID: 30233168]. [PubMed Central ID: PMC6132232]. <https://doi.org/10.2147/COPD.S175017>.
- Suissa S. Number needed to treat in COPD: exacerbations versus pneumonias. *Thorax.* 2013;**68**(6):540-3. [PubMed ID: 23125170]. <https://doi.org/10.1136/thoraxjnl-2012-202709>.
- Yousuf AJ, Parker S, Finch J, Parekh G, Glover S, Watson L, et al. Do Raised Serum Ige and Eosinophils Have an Affect on Quality of Life and Patient Related Outcome in COPD? *C34. COPD POTPOURRI.* San Diego, CA. American Thoracic Society; 2018. A4765 p.
- Jabarkhil A, Janner J, Moberg M, Eriksen N, Nymann Pedersen M, Bjørn Jensen C, et al. High Blood Eosinophils in Acute Exacerbation of Chronic Obstructive Lung Disease Is Not Associated with Higher Risk of Readmission or Mortality. *B36. BIOMARKERS IN COPD.* San Diego, CA. American Thoracic Society; 2018. A3123 p.
- Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. *Int J Chron Obstruct Pulmon Dis.* 2012;**7**:283-9. [PubMed ID: 22833163].

- 22589579]. [PubMed Central ID: [PMC3346210](https://doi.org/10.2147/COPD.S30651)]. <https://doi.org/10.2147/COPD.S30651>.
23. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. *Thorax*. 2016;**71**(2):118-25. [PubMed ID: [26585525](https://pubmed.ncbi.nlm.nih.gov/26585525/)]. [PubMed Central ID: [PMC4752631](https://pubmed.ncbi.nlm.nih.gov/PMC4752631/)]. <https://doi.org/10.1136/thoraxjnl-2015-207021>.
24. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. 2015;**192**(4):523-5. [PubMed ID: [26051430](https://pubmed.ncbi.nlm.nih.gov/26051430/)]. [PubMed Central ID: [PMC4595668](https://pubmed.ncbi.nlm.nih.gov/PMC4595668/)]. <https://doi.org/10.1164/rccm.201502-0235LE>.
25. Tzortzaki EG, Proklou A, Siafakas NM. Asthma in the Elderly: Can We Distinguish It from COPD? *J Allergy (Cairo)*. 2011;**2011**:843543. [PubMed ID: [21785614](https://pubmed.ncbi.nlm.nih.gov/21785614/)]. [PubMed Central ID: [PMC3138061](https://pubmed.ncbi.nlm.nih.gov/PMC3138061/)]. <https://doi.org/10.1155/2011/843543>.
26. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. *Thorax*. 2005;**60**(3):193-8. [PubMed ID: [15741434](https://pubmed.ncbi.nlm.nih.gov/15741434/)]. [PubMed Central ID: [PMC1747331](https://pubmed.ncbi.nlm.nih.gov/PMC1747331/)]. <https://doi.org/10.1136/thx.2004.032516>.
27. Fujimoto K, Kubo K, Yamamoto H, Yamaguchi S, Matsuzawa Y. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. *Chest*. 1999;**115**(3):697-702. [PubMed ID: [10084478](https://pubmed.ncbi.nlm.nih.gov/10084478/)]. <https://doi.org/10.1378/chest.115.3.697>.
28. Tsiligianni I, Kaplan AG. Are blood eosinophils a prime-time biomarker for COPD management decisions? *Int J Chron Obstruct Pulmon Dis*. 2018;**13**:1889-91. [PubMed ID: [29928119](https://pubmed.ncbi.nlm.nih.gov/29928119/)]. [PubMed Central ID: [PMC6003531](https://pubmed.ncbi.nlm.nih.gov/PMC6003531/)]. <https://doi.org/10.2147/COPD.S163749>.